These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11551261)

  • 21. Lessons on prescribing and drug safety from the withdrawal of rofecoxib.
    Nelson M; Cicuttini F
    Aust Fam Physician; 2004 Dec; 33(12):965-6. PubMed ID: 15630913
    [No Abstract]   [Full Text] [Related]  

  • 22. Acute congestive heart failure induced by rofecoxib.
    Campbell RJ; Sneed KB
    J Am Board Fam Pract; 2004; 17(2):131-5. PubMed ID: 15082672
    [No Abstract]   [Full Text] [Related]  

  • 23. Is rofecoxib safer than naproxen?
    Adelman A
    J Fam Pract; 2001 Mar; 50(3):204. PubMed ID: 11252204
    [No Abstract]   [Full Text] [Related]  

  • 24. [Probable cardiac failure due to rofecoxib].
    García Nicolás FJ
    Aten Primaria; 2005 Apr; 35(6):325-6. PubMed ID: 15826518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A rare case of rofecoxib-induced cholestatic hepatitis.
    Harsch IA; Michaeli P; Hahn EG; Konturek PC; Klein R
    Dig Liver Dis; 2003 Dec; 35(12):911-2. PubMed ID: 14703890
    [No Abstract]   [Full Text] [Related]  

  • 26. Upper gastrointestinal toxicity of rofecoxib and naproxen.
    Gupta S
    N Engl J Med; 2001 May; 344(18):1398; author reply 1398-9. PubMed ID: 11336057
    [No Abstract]   [Full Text] [Related]  

  • 27. [Wrong information concerning rofecoxib].
    Rygnestad T; Slørdal L
    Tidsskr Nor Laegeforen; 2002 Aug; 122(20):2035. PubMed ID: 12555455
    [No Abstract]   [Full Text] [Related]  

  • 28. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib.
    Bagán JV; Thongprasom K; Scully C
    Oral Dis; 2004 Nov; 10(6):401-3. PubMed ID: 15533219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review.
    Perrone MR; Artesani MC; Viola M; Gaeta F; Caringi M; Quaratino D; Romano A
    Int Arch Allergy Immunol; 2003 Sep; 132(1):82-6. PubMed ID: 14555862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The great rofecoxib feeding frenzy.
    Van Way CW
    JPEN J Parenter Enteral Nutr; 2005; 29(2):136-8. PubMed ID: 15772394
    [No Abstract]   [Full Text] [Related]  

  • 31. Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen.
    Ann Intern Med; 2003 Oct; 139(7):I29. PubMed ID: 14530248
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics.
    Karakaya G; Kalyoncu AF
    Allergol Immunopathol (Madr); 2000; 28(6):319-21. PubMed ID: 11269899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracranial hypertension induced by rofecoxib.
    Jacob S; Rajabally YA
    Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Central retinal vein occlusion in a patient with rheumatoid arthritis taking rofecoxib.
    Meyer Ch; Gähler R
    Lancet; 2002 Oct; 360(9339):1100. PubMed ID: 12384019
    [No Abstract]   [Full Text] [Related]  

  • 35. Fatal haemorrhagic pulmonary oedema and associated angioedema after the ingestion of rofecoxib.
    Kumar NP; Wild G; Ramasamy KA; Snape J
    Postgrad Med J; 2002 Jul; 78(921):439-40. PubMed ID: 12151676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapy with rofecoxib. Decreasing risk by controlled COX-2 inhibitor administration].
    MMW Fortschr Med; 2000 Nov; 142(48):64-5. PubMed ID: 11144940
    [No Abstract]   [Full Text] [Related]  

  • 37. Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
    Weaver A; Alderman M; Sperling R
    Am J Cardiol; 2003 May; 91(10):1291-2. PubMed ID: 12745131
    [No Abstract]   [Full Text] [Related]  

  • 38. Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs.
    Asero R
    Clin Exp Allergy; 2005 Jun; 35(6):713-6. PubMed ID: 15969659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Vioxx debacle.
    Alpert JS
    Am J Med; 2005 Mar; 118(3):203-4. PubMed ID: 15745713
    [No Abstract]   [Full Text] [Related]  

  • 40. Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity.
    Kruse R; Ruzicka T; Grewe M
    Acta Derm Venereol; 2003; 83(3):183-5. PubMed ID: 12816152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.